EMA — authorised 25 July 2014
- Application: EMEA/H/C/002418
- Marketing authorisation holder: Laboratoires CTRS - Boulogne Billancourt
- Local brand name: Neofordex
- Indication: Treatment of symptomatic multiple myeloma
- Status: withdrawn
🇪🇺 Neofordex® in European Union
EMA authorised Neofordex® on 25 July 2014
Marketing authorisations
EMA — authorised 16 March 2016
- Application: EMEA/H/C/004071
- Marketing authorisation holder: THERAVIA
- Local brand name: Neofordex
- Indication: Treatment of multiple myeloma.
- Status: approved
Frequently asked questions
Is Neofordex® approved in European Union?
Yes. EMA authorised it on 25 July 2014; EMA authorised it on 16 March 2016.
Who is the marketing authorisation holder for Neofordex® in European Union?
Laboratoires CTRS - Boulogne Billancourt holds the EU marketing authorisation.